Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103836 | 1.00 | SYK (0.64) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL23161521 | 0.97 | SYK (0.65) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL19301063 | 0.97 | SYK (0.65) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL2512642 | 0.97 | SYK (0.65) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL29401232 | 0.96 | MAPT (0.67) | SYKMAPTKLK7KLK5FOLH1 | |
| SCHEMBL30915257 | 0.96 | MAPT (0.67) | SYKMAPTKLK7KLK5FOLH1 | |
| SCHEMBL8838459 | 0.96 | MAPT (0.67) | SYKMAPTKLK7KLK5FOLH1 | |
| SCHEMBL21789935 | 0.92 | MAPT (0.63) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL21790401 | 0.92 | MAPT (0.63) | SYKMAPTKLK7KLK5L3MBTL1 | |
| SCHEMBL2512643 | 0.92 | MAPT (0.63) | SYKMAPTKLK7KLK5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349053-A | Inhibitors of lysine porphyromonas gingivalis protease | 库特克希米公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-2051968-B1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | UNIV CALIFORNIA (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-107108468-B | Inhibitors of lysine porphyromonas gingivalis protease | 库特克希米公司 | 2020-01-03 | — | — | CN | disclosed |
| US-10352938-B2 | Macrocyclic HOPO chelators | LUMIPHORE, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| EP-2423201-B1 | Luminescent macrocyclic lanthanide complexes | UNIV CALIFORNIA (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20160320399-A1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9273059-B2 | Macrocyclic HOPO chelators | LUMIPHORE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2029526-B1 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-08-06 | — | — | EP | disclosed |
| US-8729258-B2 | Luminescent macrocyclic lanthanide complexes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120329174-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-27 | — | — | US | disclosed |
| US-8318779-B2 | Lysine related derivatives as HIV aspartyl protease inhibitors | JANSSEN R&D IRELAND (IE) | 2012-11-27 | — | — | US | disclosed |
| US-20120214253-A1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8173800-B2 | Hydroxy-isophthalamide moieties; antibodies; high stability, luminescence; kits | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2423201-A1 | Luminescent macrocyclic lanthanide complexes | The Regents of The University of California (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011025790-A1 | MACROCYCLIC HOPO CHELATORS | LUMIPHORE, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20090118339-A1 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| EP-2029526-A1 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080213917-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2007138069-A1 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213917-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | SSB, HACD3, CLTA | SYK 4342/4885MAPT 1513/4885KLK7 1672/4885 |
| US-20120329174-A1 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES | SSB, HACD3, CLTA | SYK 4342/4885MAPT 1513/4885KLK7 1672/4885 |
| US-20160320399-A1 | MACROCYCLIC HOPO CHELATORS | PHPT1, SSB, CD69 | SYK 1866/4885MAPT 2711/4885KLK7 877/4885 |
| US-20090118339-A1 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | DNPEP, PEPD, PREP | SYK 3195/4885MAPT 373/4885KLK7 127/4885 |
| US-20120214253-A1 | MACROCYCLIC HOPO CHELATORS | PHPT1, SSB, CD69 | SYK 1866/4885MAPT 2711/4885KLK7 877/4885 |
| US-10352938-B2 | Macrocyclic HOPO chelators | PHPT1, SSB, CD69 | SYK 1866/4885MAPT 2711/4885KLK7 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.